Holen Sie sich die Stockscreener-App
2.07
3.50%
0.07
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsJuly 2025 WrapUp & Reliable Intraday Trade Plans - ulpravda.ru
Will Protalix BioTherapeutics Inc. stock gain from strong economyStop Loss & Target Return Focused Stock Picks - ulpravda.ru
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliableMarket Performance Recap & High Conviction Trade Alerts - ulpravda.ru
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - ulpravda.ru
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - ulpravda.ru
What technical charts say about Protalix BioTherapeutics Inc. stock2025 Support & Resistance & Risk Managed Investment Signals - ulpravda.ru
How Low Can Protalix BioTherapeutics Stock Really Go? - Trefis
Why Protalix BioTherapeutics Inc. (DE) stock benefits from AI revolution2026 world cup usa national team qualification young talents pressing system expert forecast preview - ulpravda.ru
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - moha.gov.vn
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Will Protalix BioTherapeutics Inc. (DE) stock outperform Dow JonesWeekly Gains Summary & Entry Point Strategy Guides - DonanımHaber
Can Protalix BioTherapeutics Inc. stock beat analyst upgradesWeekly Gains Summary & Verified Entry Point Detection - Улправда
Institution Moves: Is Protalix BioTherapeutics Inc. stock a contrarian buyBond Market & Community Verified Trade Signals - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock a buy before new product rolloutJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Sentiment Review: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3%Still a Buy? - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3% – Still a Buy? - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Breakout Zone: How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Technicals & AI Forecast for Swing Trade Picks - Улправда
Is Protalix BioTherapeutics Inc. stock a contrarian buy2025 Big Picture & Technical Pattern Based Buy Signals - Улправда
Protalix and Secarna partner to develop rare kidney disease treatments By Investing.com - Investing.com South Africa
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development - Proactive financial news
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Finviz
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Protalix BioTherapeutics (PLX) Partners with Secarna for Kidney Disorder Treatments - GuruFocus
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter Into Collaboration and Option Agreement - 富途牛牛
Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications - marketscreener.com
Protalix and Secarna partner to develop rare kidney disease treatments - Investing.com
Protalix Biotherapeutics and Secarna Pharmaceuticals enter into collaboration and option agreement - marketscreener.com
Protalix BioTherapeutics Earnings Notes - Trefis
Protalix BioTherapeutics (PLX) Price Target Decreased by 10.71% to 12.75 - Nasdaq
Why analysts recommend Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):